Calyxt, Inc. Announces Effectiveness Of Registration Statement On Form S-4 In Connection With Merger With Cibus Global LLC

 Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, today announced that the registration statement on Form S-4, initially filed with the U.S. Securities and Exchange Commission ("SEC") by Calyxt on February 14, 2023, and amended on April 14, 2023 (as amended, the "Registration Statement"), has been declared effective by the SEC.

The Registration Statement was filed in connection with the previously announced merger of Calyxt and Cibus and contains a proxy statement / prospectus of Calyxt.

Calyxt also announced that it has scheduled a special meeting of its stockholders (the "Special Meeting") to seek approval of matters related to the merger from such stockholders. The Calyxt Special Meeting will be held virtually via live webcast at www.virtualshareholdermeeting.com/CLXT2023SM on May 18, 2023 at 9:00 a.m. Central Time. Calyxt's stockholders of record as of April 12, 2023 are entitled to vote at the Special Meeting.

The proxy statement/prospectus contains important information about the proposed merger transactions, the merger agreement and the proposals to be considered at the Special Meeting.

The combined company is expected to be renamed Cibus, Inc. and remain listed on the Nasdaq Capital Market under the proposed ticker symbol CBUS.

The Registration Statement is available and may be accessed without charge on the SEC's website at www.sec.gov (as filed under Calyxt, Inc.) or at the SEC filings portion of Calyxt's website at https://ir.calyxt.com/sec-filings/all-sec-filings.

The merger is expected to close in the second quarter of 2023, subject to customary closing conditions, including approval of the merger by the shareholders of Calyxt at the Special Meeting.